Glycoproteins

Name
Glycoproteins
Accession Number
DBCAT000083
Description

Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.

Drugs
DrugDrug Description
Darbepoetin alfaA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
ErythropoietinA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
PegfilgrastimA recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
SargramostimA modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
FilgrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
Methoxy polyethylene glycol-epoetin betaA synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease.
Gastric intrinsic factorIntrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic...
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
Epoetin deltaEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
MuplestimMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in...
MolgramostimMolgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.
TecemotideTecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of...
Protein S humanA medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
LipegfilgrastimA medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy.
SulglicotideNot Annotated
RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
PRM-151PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
LeridistimLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AvidinAvidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
SOR-C13SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
Drugs & Drug Targets
DrugTargetType
Darbepoetin alfaErythropoietin receptortarget
ErythropoietinErythropoietin receptortarget
PegfilgrastimGranulocyte colony-stimulating factor receptortarget
PegfilgrastimNeutrophil elastaseenzyme
SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
SargramostimBone marrow proteoglycantarget
SargramostimInterleukin-3 receptor subunit alphatarget
SargramostimCytokine receptor common subunit betatarget
SargramostimSyndecan-2target
Drotrecogin alfaCoagulation factor VIIItarget
Drotrecogin alfaCoagulation factor Vtarget
Drotrecogin alfaPlasminogen activator inhibitor 1target
Drotrecogin alfaThrombomodulintarget
Drotrecogin alfaVitamin K-dependent protein Starget
Drotrecogin alfaProthrombintarget
Drotrecogin alfaPlatelet factor 4target
Drotrecogin alfaPlasma serine protease inhibitortarget
Drotrecogin alfaSerpin B6target
Drotrecogin alfaEndothelial protein C receptortarget
Alpha-1-proteinase inhibitorNeutrophil elastasetarget
FilgrastimGranulocyte colony-stimulating factor receptortarget
FilgrastimNeutrophil elastasetarget
RomiplostimThrombopoietin receptortarget
Thrombomodulin AlfaCoagulation factor Vtarget
Thrombomodulin AlfaProthrombintarget
PRO-542Free fatty acid receptor 4target
PegdinetanibVascular endothelial growth factor receptor 2target
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
ThrombopoietinThrombopoietin receptortarget
TG4010Mucin-1target
TG4010Interleukin-2target
Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
LenograstimGranulocyte colony-stimulating factor receptortarget
Protein S humanCoagulation factor Vtarget
Protein S humanCoagulation factor Xtarget
Protein S humanVitamin K-dependent protein Ctarget
LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
RegramostimGM-CSF receptor alpha subunittarget
RegramostimCholinesteraseenzyme
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget